{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:48:23Z","timestamp":1794001703880,"version":"4.8.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Our study investigates the effect of vonoprazan on albuminuria in diabetic kidney disease (DKD) patients compared to lansoprazole through a randomized controlled trial. Participants were randomized to receive either lansoprazole 30\u00a0mg or vonoprazan 20\u00a0mg. Specifically, 100 patients were included for H. pylori eradication, and 40 patients for other indications. The albumin\/creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR) were measured at baseline and three months later. Both vonoprazan and lansoprazole significantly reduced ACR from baseline levels after 3 months (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). However, the reduction in albuminuria was significantly greater in the vonoprazan group compared to the lansoprazole group, regardless of H. pylori diagnosis or eradication success (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). Treatment type was a significant predictor, with a standardized beta of 0.555. Patients receiving vonoprazan experienced a 19.2-unit increase in the percentage change of ACR compared to those receiving lansoprazole (\u03b2\u2009=\u200919.219, 95% CI [13.62-24.817]). Additionally, vonoprazan-treated patients showed significant improvement in eGFR after 3 months compared to baseline levels (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05), with this improvement being superior to that observed with lansoprazole (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). Vonoprazan may have a direct renal effect, warranting further research to elucidate its mechanism in reducing albuminuria.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-25376-8","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T14:42:24Z","timestamp":1763736144000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Vonoprazan attenuates proteinuria in diabetic kidney disease through potential direct renal mechanism"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9914-7066","authenticated-orcid":false,"given":"Rabab Mahmoud","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5589-1037","authenticated-orcid":false,"given":"Amin Roshdy","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AbdelAal","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"25376_CR1","doi-asserted-by":"crossref","unstructured":"Parmar, M. P. et al. Impact of proton pump inhibitors on kidney function and chronic kidney disease progression: a systematic review. Cureus. 15(12), e49883 (2023).","DOI":"10.7759\/cureus.49883"},{"key":"25376_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000506634","volume":"6","author":"Y Chen","year":"2020","unstructured":"Chen, Y., Lee, K., Ni, Z. & He, J. C. Diabetic kidney disease: Challenges, Advances, and opportunities. Kidney Dis. (Basel). 6, 215\u2013225 (2020).","journal-title":"Kidney Dis. (Basel)"},{"key":"25376_CR3","doi-asserted-by":"publisher","first-page":"1349022","DOI":"10.3389\/fphar.2024.1349022","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. A new perspective on proteinuria and drug therapy for diabetic kidney disease. Front. Pharmacol. 15, 1349022 (2024).","journal-title":"Front. Pharmacol."},{"issue":"1","key":"25376_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13098-023-01051-8","volume":"15","author":"MH Lin","year":"2023","unstructured":"Lin, M. H. et al. Association between clinical use of Lansoprazole and the risk of type 2 diabetes mellitus: a pharmacoepidemiological cohort study. Diabetol. Metab. Syndr. 15(1), 96 (2023).","journal-title":"Diabetol. Metab. Syndr."},{"key":"25376_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diabres.2018.01.022","volume":"138","author":"Y Hayashino","year":"2018","unstructured":"Hayashino, Y. et al. Association of proton pump inhibitor use with the risk of the development or progression of albuminuria among Japanese patients with diabetes: A prospective cohort study [Diabetes distress and care registry at Tenri (DDCRT 16)]. Diabetes Res. Clin. Pract. 138, 1\u20137 (2018).","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"8","key":"25376_CR6","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1210\/jc.2017-00354","volume":"102","author":"TM Davis","year":"2017","unstructured":"Davis, T. M., Drinkwater, J. & Davis, W. A. Proton pump inhibitors, nephropathy, and cardiovascular disease in type 2 diabetes: the Fremantle diabetes study. J. Clin. Endocrinol. Metabolism 102(8), 2985\u20132993 (2017).","journal-title":"J. Clin. Endocrinol. Metabolism"},{"key":"25376_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.diabres.2018.11.019","volume":"147","author":"H Yang","year":"2019","unstructured":"Yang, H., Juang, S. Y. & Liao, K. F. Proton pump inhibitors use and risk of chronic kidney disease in diabetic patients. Diabetes Res. Clin. Pract. 147, 67\u201375 (2019).","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"10","key":"25376_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/0115733998254869231101095222","volume":"20","author":"S Chenchula","year":"2024","unstructured":"Chenchula, S. et al. Association and mechanisms of proton pump inhibitors use with Type-2 diabetes mellitus incidence in adults: A systemic review and Meta-Analysis. Curr. Diabetes. Rev. 20(10), 1\u20132 (2024).","journal-title":"Curr. Diabetes. Rev."},{"issue":"2","key":"25376_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4103\/ijn.IJN_397_20","volume":"32","author":"JP Raj","year":"2022","unstructured":"Raj, J. P., Pinto, R. W., Tomy, S. K. & Kulkarni, S. M. Diabetic nephropathy and proton pump inhibitors\u2013pilot case-control study. Indian J. Nephrol. 32(2), 127\u2013131 (2022).","journal-title":"Indian J. Nephrol."},{"issue":"7\u20138","key":"25376_CR10","first-page":"241","volume":"124","author":"A Timucin","year":"2012","unstructured":"Timucin, A. et al. Effects of Helicobacter pylori eradication on proteinuria: a prospective study. Wien Klin. Wochenschr 124(7\u20138), 241\u2013244 (2012).","journal-title":"Wien Klin. Wochenschr"},{"key":"25376_CR11","first-page":"180690","volume":"2014","author":"C Bahar","year":"2014","unstructured":"Bahar, C. et al. The effects of Helicobacter pylori eradication on proteinuria in patients with primary glomerulonephritis. Int. J. Nephrol. 2014, 180690 (2014).","journal-title":"Int. J. Nephrol."},{"issue":"4","key":"25376_CR12","first-page":"764","volume":"11","author":"D Fatih","year":"2015","unstructured":"Fatih, D. et al. The effect of Helicobacter pylori eradication on proteinuria in patients with primary glomerulonephritis. Arch. Med. Sci. 11(4), 764\u2013769 (2015).","journal-title":"Arch. Med. Sci."},{"issue":"1","key":"25376_CR13","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1080\/0886022X.2019.1683029","volume":"41","author":"P Wei","year":"2019","unstructured":"Wei, P. et al. Association between Helicobacter pylori infection and kidney damage in patients with peptic ulcer. Ren. Fail. 41(1), 1028\u20131034 (2019).","journal-title":"Ren. Fail."},{"issue":"3","key":"25376_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/87551225231166531","volume":"39","author":"E Onge","year":"2023","unstructured":"Onge, E. & Phillips, S. T. Vonoprazan: a new potassium-competitive acid blocker. J. Pharm. Technol. 39(3), 139\u2013146 (2023).","journal-title":"J. Pharm. Technol."},{"key":"25376_CR15","doi-asserted-by":"crossref","unstructured":"Schulz, K. F. & Altman, D. G., Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials.","DOI":"10.1016\/j.ijsu.2010.09.006"},{"key":"25376_CR16","unstructured":"18-National Kidney Foundation.CKD-EPI Creatinine Eq. (2021). Available from: https:\/\/www.kidney.org\/ckd-epi-creatinine-equation-2021"},{"key":"25376_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2337\/diacare.27.2007.S79","volume":"27","author":"ME Molitch","year":"2004","unstructured":"Molitch, M. E., DeFronzo, R. A., Franz, M. J. & Keane, W. F. Nephropathy in diabetes. Diabetes Care 27, 79 (2004).","journal-title":"Diabetes Care"},{"key":"25376_CR18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/nur.20247","volume":"31","author":"MA Hertzog","year":"2008","unstructured":"Hertzog, M. A. Considerations in determining sample size for pilot studies. Res. Nurs. Health. 31, 180\u2013191 (2008).","journal-title":"Res. Nurs. Health"},{"issue":"3","key":"25376_CR19","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.kint.2022.06.007","volume":"102","author":"M Ishida","year":"2022","unstructured":"Ishida, M. et al. Vonoprazan-associated nephrotoxicity: extensive real-world evidence from spontaneous adverse drug reaction reports. Kidney Int. 102(3), 666\u2013668 (2022).","journal-title":"Kidney Int."},{"issue":"1","key":"25376_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3892\/etm.2022.11726","volume":"25","author":"J Liu","year":"2022","unstructured":"Liu, J., Li, X., Xu, N., Han, H. & Li, X. Role of ion channels in the mechanism of proteinuria. Experimental Therapeutic Med. 25(1), 27 (2022).","journal-title":"Experimental Therapeutic Med."},{"issue":"2","key":"25376_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.tem.2023.09.009","volume":"35","author":"H Hu","year":"2024","unstructured":"Hu, H., Liang, W. & Ding, G. Ion homeostasis in diabetic kidney disease. Trends in Endocrinology & Metabolism. 35(2), 142\u2013150 (2024).","journal-title":"Trends in Endocrinology & Metabolism."},{"issue":"Pt 14","key":"25376_CR22","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1113\/jphysiol.2011.212316","volume":"589","author":"PB Persson","year":"2011","unstructured":"Persson, P. B. Potassium homeostasis during nephrotic syndrome: signalling via filtered protein?. J. Physiol. 589(Pt 14), 3417 (2011).","journal-title":"J. Physiol."},{"issue":"14","key":"25376_CR23","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1113\/jphysiol.2011.209692","volume":"589","author":"M Fila","year":"2011","unstructured":"Fila, M. et al. Inhibition of K\u2009+\u2009secretion in the distal nephron in nephrotic syndrome: possible role of albuminuria. J. Physiol. 589(14), 3611\u20133621 (2011).","journal-title":"J. Physiol."},{"issue":"4","key":"25376_CR24","doi-asserted-by":"publisher","first-page":"101119","DOI":"10.1016\/j.gendis.2023.101119","volume":"11","author":"J Guo","year":"2024","unstructured":"Guo, J., Zhang, C., Zhao, H., Yan, Y. & Liu, Z. The key mediator of diabetic kidney disease: potassium channel dysfunction. Genes Dis. 11(4), 101119 (2024).","journal-title":"Genes Dis."},{"issue":"1","key":"25376_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s43162-024-00352-2","volume":"36","author":"RM Ahmed","year":"2024","unstructured":"Ahmed, R. M., Rakha, N. K., Yousry, A. & Soliman, A. R. Potential impact of sodium glucose co-transporter (SGLT2) inhibitors on cholesterol fractions in stage 3 chronic kidney disease. Egypt. J. Intern. Med. 36(1), 83 (2024).","journal-title":"Egypt. J. Intern. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25376-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25376-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25376-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T14:42:25Z","timestamp":1763736145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25376-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["25376"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-25376-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"4 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41446"}}